deltatrials
Completed PHASE3 INTERVENTIONAL 8-arm NCT03526861

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Tralokinumab Monotherapy in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) Who Are Candidates for Systemic Therapy

Sponsor: LEO Pharma

Conditions Atopic Dermatitis
Interventions Placebos Tralokinumab
Updated 23 times since 2018 Last updated: Feb 21, 2025 Started: Jun 19, 2018 Primary completion: Apr 15, 2020 Completion: Mar 16, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atopic Dermatitis, this trial is completed. The trial is conducted by LEO Pharma and has accumulated 23 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Oct 2020 · 10 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Sep 2022 · 10 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 18 earlier versions

  1. Sep 2022 — Jun 2023 [monthly]

    Completed PHASE3

  2. Nov 2021 — Sep 2022 [monthly]

    Completed PHASE3

  3. Sep 2021 — Nov 2021 [monthly]

    Completed PHASE3

  4. Apr 2021 — Sep 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Feb 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2019 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  10. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  11. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  12. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  13. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  14. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  15. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  16. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  17. Aug 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  18. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • LEO Pharma
Data source: LEO Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Ann Arbor, United States , Austin, United States , Baton Rouge, United States , Bergen op Zoom, Netherlands , Berlin, Germany , Bexley, United States , Birmingham, United States , Breda, Netherlands , Brussels, Belgium and 66 more locations